Trial Profile
NMK36 late phase II. Open-label study to assess efficacy and safety of a single dose (i.v.) of NMK36 in patients with prostate cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Fluciclovine 18F (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Diagnostic use
- Sponsors Nihon Medi-Physics
- 20 Jan 2016 New trial record